Ellipses Pharma Limited announced the U.S. Food and Drug Administration has confirmed the company’s next generation selective RET inhibitor, EP0031/A400, is clear to progress into Phase 2 clinical development.
Ellipses Pharma Limited announced the U.S. Food and Drug Administration has confirmed the company’s next generation selective RET inhibitor, EP0031/A400, is clear to progress into Phase 2 clinical development.